ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2019
Cardiovascular Effects of Tyrosine Kinase Inhibitors in Patients With Advanced Renal Cell Carcinoma at the VA San Diego Healthcare System.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma.Discover oncology · 2025Article
- Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.JACC. CardioOncology · 2022Review
- Author's Reply to Şener and Begijanashvili: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy".Targeted oncology · 2022Article
- Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature.Journal of kidney cancer and VHL · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients who have or are at high risk for developing cardiovascular disease and who are taking tyrosine kinase inhibitors for renal cell carcinoma should receive routine cardiovascular event monitoring during the first 4 months of therapy.
Identifiers
31138979PMC6533895W3025797998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.